According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
COLL has been the topic of several other reports. ValuEngine raised shares of Collegium Pharmaceutical from a sell rating to a hold rating in a report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an overweight rating and set a $24.00 price objective (down from $35.00) on shares of Collegium Pharmaceutical in a report on Thursday. HC Wainwright assumed coverage on shares of Collegium Pharmaceutical in a report on Friday, May 3rd. They set a buy rating and a $23.00 price objective on the stock. BidaskClub downgraded shares of Collegium Pharmaceutical from a hold rating to a sell rating in a report on Tuesday, July 16th. Finally, Janney Montgomery Scott assumed coverage on shares of Collegium Pharmaceutical in a report on Friday, April 12th. They set a buy rating and a $29.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Collegium Pharmaceutical currently has a consensus rating of Buy and a consensus price target of $24.33.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. The business had revenue of $75.04 million for the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.40) earnings per share. Equities analysts predict that Collegium Pharmaceutical will post -0.46 EPS for the current year.
In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,857 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $12.31, for a total transaction of $35,169.67. Following the transaction, the executive vice president now directly owns 40,596 shares of the company’s stock, valued at $499,736.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $11.26, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 132,069 shares in the company, valued at $1,487,096.94. The disclosure for this sale can be found here. Insiders have sold 91,144 shares of company stock worth $1,075,506 over the last ninety days. 8.08% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the business. MERIAN GLOBAL INVESTORS UK Ltd purchased a new position in Collegium Pharmaceutical during the first quarter worth about $26,000. First Quadrant L P CA raised its stake in Collegium Pharmaceutical by 87.2% during the second quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 2,089 shares during the period. DekaBank Deutsche Girozentrale raised its stake in Collegium Pharmaceutical by 22.2% during the first quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the specialty pharmaceutical company’s stock worth $221,000 after purchasing an additional 2,400 shares during the period. Sheaff Brock Investment Advisors LLC raised its stake in Collegium Pharmaceutical by 14.9% during the first quarter. Sheaff Brock Investment Advisors LLC now owns 20,650 shares of the specialty pharmaceutical company’s stock worth $313,000 after purchasing an additional 2,675 shares during the period. Finally, Bank of America Corp DE raised its stake in Collegium Pharmaceutical by 17.2% during the fourth quarter. Bank of America Corp DE now owns 23,981 shares of the specialty pharmaceutical company’s stock worth $412,000 after purchasing an additional 3,525 shares during the period. 94.71% of the stock is currently owned by institutional investors.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Featured Story: Dead Cat Bounce
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.